Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

30.08 -0.17 (-0.56%)

Official Closing Price Updated: 7:00 PM EDT, Apr 2, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	2,843,882
Open	29.45
Bid (Size)	29.57 (100)
Ask (Size)	30.25 (100)
Prev. Close	30.25
Today's Range	29.40 - 30.35
52wk Range	12.46 - 37.34
Shares Outstanding	1,110,352,397
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Corcept Therapeutics Outperforms: How a Surprise FDA Approval Ignited a Late-March Rally

March 31, 2026

In a month characterized by macroeconomic headwinds and a broader cooling of the biotechnology sector, Corcept Therapeutics (NASDAQ: CORT) has emerged as a definitive outlier. While the S&P Biotech ETF...

Via MarketMinute

Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)

March 30, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Performance

YTD	-2.8%	-2.8%
1 Month	-6.8%	-6.8%
3 Month	-2.8%	-2.8%
6 Month	+50.0%	+50.0%
1 Year	+96.7%	+96.7%

More News

MarketMinute: Corcept Therapeutics (CORT) Surges 19.66% on Surprise FDA Approval and Oncology Breakthrough

March 26, 2026

Via MarketMinute

The Second Act: A Deep-Dive into Corcept Therapeutics and the FDA Approval of Lifyorli

March 26, 2026

Via Finterra

This $7 Million Masimo Exit Came Before a 34% Surge on $9.9 Billion Acquisition ↗

March 22, 2026

Via The Motley Fool

Teva Releases Q1 2026 Aide Memoire

March 19, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026

March 19, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

The $1.3 Trillion Architect: How Blackstone is Redefining Global Finance through Private Credit and Essential Consumerism

March 18, 2026

Via Finterra

Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment ↗

March 13, 2026

Via The Motley Fool

Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned ↗

March 13, 2026

Via The Motley Fool

The Potassium Channel Breakthrough: A Deep-Dive on Xenon Pharmaceuticals (XENE)

March 10, 2026

Via Finterra

The 3 Best Stocks to Invest $1,000 in Right Now ↗

March 06, 2026

Via The Motley Fool

Forget Teva: This Dividend Top Dog Is the Real Value Buy Today ↗

March 04, 2026

Via The Motley Fool

Billionaire Stanley Druckenmiller Dumped 2 of His Top Performers -- Teva and Taiwan Semiconductor -- and Made This Sector-Based ETF His Fund's New No. 2 Holding ↗

March 04, 2026

Via The Motley Fool

Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug

March 03, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Viatris (VTRS): From Debt-Laden Merger to Specialty Powerhouse—A 2026 Research Deep Dive

March 03, 2026

Via Finterra

The Best Healthcare Stock to Invest $1,000 in Right Now ↗

March 02, 2026

Via The Motley Fool

Here's Why I Won't Touch Teva Pharmaceutical With a 10‑Foot Pole ↗

February 27, 2026

Via The Motley Fool

The Pivot to Growth: Viatris (VTRS) Enters Phase 2 with 2026 Dividend and Capital Allocation Strategy

February 26, 2026

Via Finterra

Bridger Dumps 301,000 Bath & Body Works Shares Worth $7.7 Million ↗

February 24, 2026

Via The Motley Fool

Teva to Present at the Upcoming Investor Conferences in March

February 24, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Inside a $75 Million Albertsons Stock Sale as Shares Sink 8% in a Year ↗

February 20, 2026

Via The Motley Fool

AvePoint Stock Down 47% as One Fund Slashes Stake by $65.9 Million ↗

February 20, 2026

Via The Motley Fool

Teva Pharmaceuticals Seeks FDA Greenlight For New Schizophrenia Treatment ↗

February 20, 2026

Via Stocktwits

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

February 20, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Frequently Asked Questions

Is Teva Pharmaceutical Industries Limited American Depositary Shares publicly traded?

Yes, Teva Pharmaceutical Industries Limited American Depositary Shares is publicly traded.

What exchange does Teva Pharmaceutical Industries Limited American Depositary Shares trade on?

Teva Pharmaceutical Industries Limited American Depositary Shares trades on the New York Stock Exchange

What is the ticker symbol for Teva Pharmaceutical Industries Limited American Depositary Shares?

The ticker symbol for Teva Pharmaceutical Industries Limited American Depositary Shares is TEVA on the New York Stock Exchange

What is the current price of Teva Pharmaceutical Industries Limited American Depositary Shares?

The current price of Teva Pharmaceutical Industries Limited American Depositary Shares is 30.08

When was Teva Pharmaceutical Industries Limited American Depositary Shares last traded?

The last trade of Teva Pharmaceutical Industries Limited American Depositary Shares was at 04/02/26 07:00 PM ET

What is the market capitalization of Teva Pharmaceutical Industries Limited American Depositary Shares?

The market capitalization of Teva Pharmaceutical Industries Limited American Depositary Shares is 33.40B

How many shares of Teva Pharmaceutical Industries Limited American Depositary Shares are outstanding?

Teva Pharmaceutical Industries Limited American Depositary Shares has 33B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.